1. Introduction {#sec1}
===============

Human immunodeficiency virus (HIV) causes a serious disease that affects people\'s health and lives. Millions of people have died from HIV infections in the 30 years since its identification. Over the past decades, a large number of studies have focused on every aspect of this virus, including virology, immunology, treatment, and genetics. An important problem related to AIDS complications was raised after the discovery of the HIV characteristics that severely damaged the lymphoid system.

Several diseases are associated with HIV infection and antiretroviral therapy. Tuberculosis is highly frequent in a large proportion of HIV infection cases in developing countries \[[@B1]\]. When research revealed that HIV-induced immune deficiency was the most common risk factor for cancer, HIV infection-related cancer became a complication of HIV infection \[[@B2]\]. HIV-associated sensory neuropathy is also a complication of HIV infection \[[@B3]\]. Recently, venous thrombosis has been described as a disease associated with HIV-positive patients \[[@B4]\]. Pulmonary arterial hypertension is a life-threatening complication of HIV infection \[[@B5]\]. A well-described complication of HIV and antiretroviral therapy is pancreatitis, which has exceedingly high rates in the HIV-positive population \[[@B6]\]. During antiretroviral therapy, classical Hodgkin lymphoma (HIV-cHL) and rhabdomyolysis are also important complications of HIV disease \[[@B7], [@B8]\]. One report showed that HIV patients frequently had neutropenia \[[@B9]\]. Generally, AIDS complications are involved in almost all important human diseases to the best of our knowledge.

Our understanding of genetic restriction factors targeting AIDS has been greatly improved by advances in genome research, such as sequencing of the whole human genome through physical and functional analyses. Many methods have been developed to study the underlying mechanisms of diseases on the whole genome level, such as genome-wide association studies, which can identify host genetic factors that affect HIV infection and the host restriction response. Nearly 40 AIDS restriction genes (ARGs) were identified from widely biological pathways such as the HIV entry receptor on lymphoid cells to oncogenes in human glioblastomas.

Many web-based databases, such as KEGG, have been established as tools to collect human disease pathway genes using genomic and molecular methods. For example, comparative transcriptome analysis can isolate marker genes that are highly differentially expressed in patients. Molecular biology has discovered several pathways that play major roles in human diseases, and hundreds of genes have been characterized as members of human disease pathways. Hence, human disease genes are available for the analysis of their effects on ARGs.

Expression correlation between genes based on a gene coexpression model can reveal the molecular mechanisms underlying gene regulation. For instance, mitochondrial pathways are coexpressed with muscle system pathway genes and neurodegenerative disease pathway genes \[[@B10]\]. The expression correlation between ARGs and other disease pathways could also explain the relationship between ARGs and AIDS complicating diseases. Canonical correlation analysis (CCA) is a powerful approach to detect coexpression between gene sets because it does not only determine correlations between two genes. For example, CCA can be used to perform a coexpression analysis of glioma pathway genes from glioblastoma transcriptomes.

In this study, we developed a CCA to determine coexpression between ARGs and other human disease pathway genes. We discussed the most significant coexpression patterns that could imply the susceptibility or sensitization to AIDS complicating diseases.

2. Methods {#sec2}
==========

2.1. Datasets {#sec2.1}
-------------

Expression data on 20,000 human genes in human genome at about 4000 experiments was normalized to a human genome expression datasets hsa.v14-04.G19816-S5626 were downloaded from COPRESDB (<http://coxpresdb.jp/>). It includes many experiments not only related to HIV infection. Human disease pathway genes (br08402.keg updated 2016) were downloaded from KEGG (<http://www.keg.jp>); this dataset includes 68 typical disease pathways with key genes ([Table 1](#tab1){ref-type="table"}). From published literature, we collected about 39 ARGs (see Table S1 available online at <https://doi.org/10.1155/2017/9163719>). From human genome expression datasets, two expression datasets were generated to include disease pathway genes and ARG expression data, respectively.

2.2. Canonical Correlation Analysis {#sec2.2}
-----------------------------------

Canonical correlation analysis is a statistical method which extracts statistically independent pair of canonical variables dependent on the correlation among two sets of original variables. The original variables are results of a linear combination of the canonical variables. In this study, expression of disease pathway genes in diverse conditions was described by vector *a* = (*a*~1~, *a*~2~,..., *a*~*m*~) and ARG expression by the vector *b* = (*b*~1~, *b*~2~,..., *b*~*m*~). The respective canonical variables *c* = (*c*~1~, *c*~2~,..., *c*~*m*~) and *d* = (*d*~1~, *d*~2~,..., *d*~*m*~) have canonical coefficients vectors *s* = (*s*~1~, *s*~2~,..., *s*~*m*~) and *s*′ = (*s*′~1~, *s*′~2~,..., *s*′~*m*~). *a* = *c*′s, and *b* = *d*′s′. The vector of eigenvalues was calculated as the magnitude of the correlation between pair of canonical variables. The variance covariance matrices were used to analyze the covariances between variables.

2.3. The Study Design and Software Tools {#sec2.3}
----------------------------------------

The R platform (<http://www.rproject.org/)> was used for canonical correlation analysis of expression data. After the canonical variables were produced, the top correlated canonical variables (*r* \> 0.95) were identified to analysis the coexpressed individual genes. Two thresholds were set up to isolate correlated integrated disease pathways with *r*  values \> 0.5 and standard deviations \> 0.2. Web-based DAVID tool (<http://david.abcc.ncifcrf.gov/)> was used for functional annotations and enrichment analysis; we used *Homo sapiens* genome as background. The "KEGG_PATHWAY" was selected for disease pathway enrichment analysis. Other parameters were automatically generated from DAVID.

Functional annotations were generated, and enrichment analyses were performed for the metabolic pathway genes using the web-based DAVID tool (<http://david.abcc.ncifcrf.gov>/). For the pathway enrichment analyses, the "KEGG_PATHWAY" was selected. The pathways with a *P*  value \< 0.01 were considered significant.

3. Results and Discussion {#sec3}
=========================

3.1. ARGs {#sec3.1}
---------

Nearly 40 AIDS restriction genes (ARGs) have been considered as host genes that impact the progression of HIV infection from virus entry to the development of AIDS (Table S1). For example, PPIA, TSG101, TRIM5*α*, APOBEC3G, and CUL5 encode HIV-1 postentry cellular viral cofactors that have been described in recent research. PPIA plays a role in cyclosporin A-mediated immunosuppression as a member of the peptidyl-prolyl cis-trans isomerase (PPIase) family \[[@B11]\], which can interact with HIV viral proteins. Cell growth and differentiation are regulated by the interaction of TSG101 with stathmin \[[@B12]\]. TRIM5*α* is an E3 ubiquitin ligase that is involved in retroviral restriction \[[@B13]\]. Other ARGs are involved in many cellular processes, such as DEFB1, which has been implicated in cystic fibrosis pathogenesis \[[@B14]\], HLA-A, which is expressed in nearly all cells \[[@B15]\], CCL, which has been implicated in immunoregulatory and inflammatory processes \[[@B16]\], CXCR6, which is a chemokine (C-X-C motif) receptor \[[@B17]\], LY6D, which is a member of the lymphocyte antigen 6 complex \[[@B18]\], and APOBEC3B, which is a cytidine deaminase. However, these ARGs have been characterized only in the absence of AIDS-related complications. The relationship between ARGs and other human diseases is unknown.

3.2. The General CCA Results {#sec3.2}
----------------------------

The application of CCA to a transcriptome can identify coexpression between genes. Coexpression between individual genes or groups of genes can be identified based on the standard deviations of genes on canonical variables. Hence, we used two strategies to determine two types of correlation. First, the top (*r* \> 0.95) canonical correlations with low standard deviations were isolated as coexpressed individual genes. Coexpression has been suggested to have less of an impact on whole disease pathways. The relationship between complicating diseases and AIDS is dependent on the roles of a few genes. Second, canonical correlations with high standard deviations (*s* \> 0.2) and *r* values (\>0.5) were selected as coexpressed between gene groups. This result indicates that coexpression has an effect on the whole disease pathway because more than 20% of the genes contribute to the canonical correlation. Most genes in disease pathways are involved in the cross talk between the complicating disease and AIDS.

3.3. Coexpressed ARGs and Human Disease Genes {#sec3.3}
---------------------------------------------

As shown in [Table 2](#tab2){ref-type="table"}, 21 top (*r* \> 0.95) canonical correlations were determined between the ARGs and human disease pathway gene transcriptomes using the CCA approach. The canonical variables originated from disease pathways including HTLV-I infection, herpes simplex infection, Epstein-Barr virus infection, viral carcinogenesis, viral myocarditis, type I diabetes mellitus, graft-versus-host disease, autoimmune thyroid disease, allograft rejection, pathways in cancer, influenza A, proteoglycans in cancer, tuberculosis, transcriptional misregulation in cancer, Huntington\'s disease, toxoplasmosis, hepatitis B, measles, microRNAs in cancer, hepatitis C, and Alzheimer\'s disease. However, canonical variables could not delegate total ARG expression and human disease pathway gene expression because the standard deviations of the ARGs (Sa) and the human disease pathway genes (Sb) were less than 0.05, as shown in [Table 2](#tab2){ref-type="table"}. Sa and Sb indicate that the canonical variables can explain less than 5% of the genes among the ARGs and human disease pathway genes. For example, HTLV-I infection pathway has 0.988 correlation factor with ARGs, and Wilks and Chisq indicate the statistic of correlation. But it has Sa \< 0.01 and Sb \< 0.05, which suggested that in whole pathway of HTLV-I infection, only a few genes were correlated with ARGs.

In [Table 3](#tab3){ref-type="table"}, the genes with the highest correlation with the canonical variables from the ARGs and human disease pathway genes were collected to show the coexpression relationships.

### 3.3.1. HLA-B and HLA-A {#sec3.3.1}

HLA-B and HLA-A are MHC class I molecules that strongly impact HIV-1 progression ([Table 3](#tab3){ref-type="table"}) \[[@B19]\]. HLA polymorphisms are significantly correlated with the time to AIDS in HIV-infected individuals \[[@B20]\]. HLA-A and HLA-B are major AIDS restriction genes.

HLA-B and HLA-B were coexpressed with 3135 (HLA-G major histocompatibility complex, class I, G) and 3134 (HLA-F major histocompatibility complex, class I, F) genes shared by many disease pathways, including HTLV-I infection, herpes simplex infection, Epstein-Barr virus infection, viral carcinogenesis, viral myocarditis, type I diabetes mellitus, graft-versus-host disease, autoimmune thyroid disease, and allograft rejection ([Table 3](#tab3){ref-type="table"}). As a marker of T cell activation, HLA-DR induction was associated with HTLV-I seropositivity \[[@B21]\]. HTLV-I infection leads to the induction of HLA \[[@B22]\]. Herpes simplex virus type 1 (HSV1) can upregulate HLA-G expression in human neurons after acute neuron infection \[[@B23]\], whereas HLA-G is the MHC class I molecule that is induced in B cells after Epstein-Barr virus transformation \[[@B24]\]. During viral carcinogenesis, HLA is abnormally expressed to enable cancer cells to escape from immune surveillance \[[@B25]\]. HLA-G polymorphisms and expression were suggested as diagnostic markers due to their involvement in breast carcinogenesis \[[@B26]\]. The increased occurrence of HLA antigens was shown to be associated with viral myocarditis \[[@B27]\]. The HLA complex has been reported to contribute to type 1 diabetes because HLA polymorphisms introduce genetic susceptibility to type 1 diabetes \[[@B28], [@B29]\]. There is evidence that HLA gene polymorphisms are potent risk factors for severe acute graft versus host diseases \[[@B30]\]. It was also shown that an HLA variant conferred a high risk for autoimmune thyroid disease \[[@B31]\]. Furthermore, allelic-induced abnormal expression of the HLA-G gene has been suggested to be associated with acute allograft rejection \[[@B32]\]. Generally, coexpression of the HLA genes indicates cross talk between HIV infection and other diseases, and this cross talk provides a potent mechanism for these diseases becoming AIDS complicating diseases.

### 3.3.2. MYH9 and ZNRD1 {#sec3.3.2}

MYH9 encodes a conventional nonmuscle myosin that is downregulated by HIV-1 pathogenesis \[[@B33]\]. As a zinc ribbon domain-containing protein, ZNRD1 plays a role in HIV-1 replication and AIDS progression \[[@B34]\]. A recent study found that ZNRD1 polymorphisms had a significant influence on AIDS progression \[[@B35]\]. ZNRD1 and MYH9 are major AIDS restriction genes.

[Table 3](#tab3){ref-type="table"} shows that MYH9 and ZNRD1 are coexpressed with different genes in disease pathways, such as 7428 (VHL; von Hippel-Lindau tumor suppressor) and 6772 (STAT1; signal transducer and activator of transcription 1) in cancer, 5781 (PTPN11; protein tyrosine phosphatase, nonreceptor type 11) and 5293 (PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta) in proteoglycans in cancer, 5371 (PML; promyelocytic leukemia) and 51513 (ETV7; ETS variant 7) in transcriptional misregulation in cancer, 7143 (TNR; tenascin R) and 6655 (SOS2; SOS Ras/Rho guanine nucleotide exchange factor 2) in microRNAs in cancer, 2775 (GNAO1; G protein subunit alpha o1) and 4261 (CIITA; class II, major histocompatibility complex, transactivator) in toxoplasmosis, and 5111 (PCNA; proliferating cell nuclear antigen) and 356 (FASLG; Fas ligand) in hepatitis B.

VHL is a well-known tumor suppressor that is involved in hereditary cancer syndromes \[[@B36]\]. Inhibition of STAT1 can block cancer cell proliferation and invasion \[[@B37]\]. Overexpression of PTPN11 can enhance the progression of many proteoglycan cancers, such as liver cancer \[[@B38]\]. Inhibition of PIK3CD signaling can abrogate transitions in cancer cells \[[@B39]\]. Downregulation of PML, which is involved in the cell cycle, survival, and apoptosis, was identified in cancer cells \[[@B40]\]. ETV7 plays important roles in chromosomal translocations in human cancer \[[@B41]\]. Induction of SOS2 was demonstrated in cancer cells, such as triple negative breast cancer \[[@B42]\]. Toxoplasma gondii can downregulate CIITA to inhibit MHC class II expression \[[@B43]\]. The PCNA promoter can recruit the hepatitis B virus preS protein to become active \[[@B44]\]. Additionally, the Fas ligand gene can be induced by the hepatitis B virus X protein \[[@B45]\]. Thus, the coexpression of MYH9, ZNRD1, and other disease pathway genes suggests probable AIDS complicating diseases.

### 3.3.3. IRF1 and ZNRD1 {#sec3.3.3}

IRF1 is an interferon regulatory factor that can affect productive HIV infection and support natural resistance against HIV infection \[[@B46]\]. Hence, IRF1 is a well-studied human AIDS restriction gene.

As shown in [Table 3](#tab3){ref-type="table"}, IRF1 and ZNRD1 are coexpressed with 356 (FASLG; Fas ligand) and 5609 (MAP2K7; mitogen-activated protein kinase 7) in the influenza A pathways. FASLG is described as a hepatitis B pathway gene and plays an important function in the influenza A virus pathway because influenza virus infection induces Fas ligand expression when the infected cells contact one another \[[@B47]\].

### 3.3.4. TLR8 and ZNRD1 {#sec3.3.4}

TLR8 is a human toll-like receptor that plays a role in signaling pathways that modulate the innate immune response to HIV infection and reduce HIV replication \[[@B48]\]. Genetic polymorphisms in TLR8 have been determined to be host cell factors associated with HIV status \[[@B49]\].

As shown in [Table 3](#tab3){ref-type="table"}, TLR8 and ZNRD1 are coexpressed with 6772 (STAT1; signal transducer and activator of transcription 1) and 3587 (IL10RA; interleukin 10 receptor subunit alpha) in the tuberculosis pathways. STAT1 plays a role in a signaling pathway to control intracellular killing of phagocytosed *Mycobacterium tuberculosis* \[[@B50]\]. IL-10 is a key factor that mediates the immunopathogenesis of tuberculosis in combination with interferon gamma and adiponectin \[[@B51]\].

### 3.3.5. TSG101 and ZNRD1 {#sec3.3.5}

TSG101 interplays with the HIV-1 nucleocapsid to prohibit HIV from turning into a DNA-containing virus \[[@B52]\]. Therefore, TSG101 is a typical anti-HIV drug target and human AIDS restriction gene \[[@B53]\].

As shown in [Table 3](#tab3){ref-type="table"}, TSG101 and ZNRD1 are coexpressed with 25981 (DNAH1; dynein axonemal heavy chain 1) and 55567 (DNAH3; dynein axonemal heavy chain 3) in the Huntington\'s disease pathways.

### 3.3.6. NCOR2 and ZNRD1 {#sec3.3.6}

NCOR2 is the RING finger ubiquitin ligase and nuclear corepressor that downregulates HIV-1 replication \[[@B54]\]. NCOR2 is a major AIDS restriction gene.

As shown in [Table 3](#tab3){ref-type="table"}, NCOR2 and ZNRD1 are coexpressed with 356 (FASLG; Fas ligand) and 6772 (STAT1; signal transducer and activator of transcription 1) in the measles pathways. Fas ligand and STAT1 were previously described in other disease pathways. Moreover, the measles virus phosphoprotein can prevent STAT1 phosphorylation \[[@B55]\].

As shown in [Table 3](#tab3){ref-type="table"}, NCOR2 and ZNRD1 are coexpressed with 4035 (LRP1; LDL receptor-related protein 1) and 9377 (COX5A; cytochrome c oxidase subunit 5A) in the Alzheimer\'s disease pathways. Recent studies showed that the LRP1 levels were reduced in Alzheimer\'s disease \[[@B56]\]. COX family genes can impair anxiety-like behavior in an Alzheimer\'s disease model \[[@B57]\].

### 3.3.7. GML and ZNRD1 {#sec3.3.7}

GML is the LY6 family member of the glycosylphosphatidylinositol- (GPI-) anchored proteins, which have conserved cysteine-rich domains with specific disulfide bonding patterns. LY6H was upregulated by HIV infection and suggested to play a role in innate immunity to HIV-1 via an interferon-like mechanism. Gene polymorphism analysis results support the hypothesis that GML is a susceptibility locus for HIV-1 infection \[[@B58]\].

GML and ZNRD1 are coexpressed with 6772 (STAT1; signal transducer and activator of transcription 1) and 6655 (SOS2; SOS Ras/Rho guanine nucleotide exchange factor 2) in the hepatitis C pathways. STAT1 plays an important role in hepatitis C infection in addition to cancer, tuberculosis, and measles. For example, hepatic STAT1 undergoes nuclear translocation during hepatitis C virus infection \[[@B59]\]. SOS2 has major functions in hepatitis C disease and cancer.

3.4. Coexpressed ARGs and Human Disease Pathways {#sec3.4}
------------------------------------------------

As shown in [Table 4](#tab4){ref-type="table"}, canonical correlations with large Sa, Sb (\>0.2), and *r* values (\>0.5) were selected to analyze coexpression between integral disease pathways and global ARGs. Unlike the top canonical correlations (*r* \> 0.95) shown in [Table 2](#tab2){ref-type="table"}, these canonical variables showed less correlation between each disease pathway and the ARG ([Table 4](#tab4){ref-type="table"}). The maximum *r* was detected between the asthma pathways and ARGs (equal to 0.66). However, these canonical variables had larger standard deviations (at least 0.2) than the top canonical correlations described previously. In the maximum case, the Sa of the ARG correlated with the acute myeloid leukemia pathway was 0.37 and the Sb of the ARG correlated with the bacterial invasion of epithelial cells pathway was 0.47. Large standard deviations indicate that more ARGs or disease pathway genes are involved in the canonical variable. Additionally, these canonical correlations show a certain level of Pearson correlation, which determines coexpression. This result suggests that most of the genes in disease pathways are coexpressed with most of the ARGs at the whole pathway level. For example, renal cell carcinoma pathway showed coexpression with ARGs with *r* = 0.5, Sa = 0.26, and Sb = 0.21. It indicates that 26% ARG genes were expressed with 21% renal cell carcinoma pathway genes. Rather than find a single gene correlated with ARGs, CCA could identify a group of genes in certain pathways correlated with ARGs. This indicate more significant and higher potential than a single gene. These pathways include renal cell carcinoma, endometrial cancer, bladder cancer, acute myeloid leukemia, non-small-cell lung cancer, asthma, autoimmune thyroid disease, allograft rejection, graft-versus-host disease, primary immunodeficiency, nicotine addiction, type I diabetes mellitus, bacterial invasion of epithelial cells, pathogenic *Escherichia coli* infection, and malaria.

The coexpression identified from CCA is preferred to describe a general relationship since the transcriptome datasets include not only HIV-related experiments but also diverse biological experiments. Due to no limitation of samples in datasets, diseases in other human organs could be characterized as coexpressed pathway with AIDS. This provide a possibility to establish a precise experiment to determine this relationship.

Among these diseases, asthma is prevalent in populations with HIV infections because 20% of individuals infected with HIV have asthma in some clinical investigations \[[@B60]\]. There is evidence to support the hypothesis that asthma is one of the major causes of morbidity and mortality in HIV patients during antiretroviral therapy \[[@B61]\]. Recently, some studies have indicated that endometrial cancer has a favorable risk post-HIV infection \[[@B62]\]. One researcher found that some HIV drugs could inhibit in vitro bladder cancer migration and invasion \[[@B63]\]. In some clinical cases, HIV MDS transformed to acute myeloid leukemia \[[@B64]\]. A famous HIV-positive patient was healed of acute myeloid leukemia by allogeneic hematopoietic cell transplantation from a graft that carried the HIV-resistant CCR5 mutation \[[@B65]\]. The association between autoimmune thyroid disease and HIV infection has been suggested by several studies \[[@B66]\]. Although the HIV-related immunodeficiency state does not cause allograft rejection, anti-CD4 antibodies have considerable functions in the treatment of allograft rejection and the blockade of HIV infection \[[@B67], [@B68]\]. Recently, studies found that patients with HIV HAART-associated lipodystrophy syndrome had an increased risk of diabetes \[[@B69]\]. The impaired immune response to pneumococcal antigen pneumolysin due to HIV infection facilitates bacterial invasion \[[@B70]\]. Finally, HIV and AIDS are well-known subject diseases followed by malaria \[[@B71]\].

4. Conclusion {#sec4}
=============

In this study, the correlation between ARGs and disease pathways genes expression were analyzed by CCA. The results showed that among ARGs, *HLA-B*, *HLA-A*, *MH9*, *ZNED1*, *IRF1*, *TLR8*, *TSG101*, *NCOR2*, and *GML* are the most significant genes correlated with other disease pathway genes. They are potential cross-links between AIDS and other diseases. Furthermore, gene pathways involved in several diseases such as asthma, autoimmune thyroid disease, and malaria were identified as an integrated pathway correlated with integrated ARGs. It suggests the risk of these diseases as AIDS complicating disease.

Supplementary Material {#supplementary-material-sec}
======================
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Table 1 HIV host genetic factor genes.
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Human disease pathway in KEGG.

  Classes                            ID                                                             Pathways
  ---------------------------------- -------------------------------------------------------------- ----------------------------------------
  Cancers: overview                  5200                                                           Pathways in cancer
  5202                               Transcriptional misregulation in cancer                        
  5203                               Viral carcinogenesis                                           
  5204                               Chemical carcinogenesis                                        
  5205                               Proteoglycans in cancer                                        
  5206                               MicroRNAs in cancer                                            
                                                                                                    
  Cancers: specific types            5210                                                           Colorectal cancer
  5211                               Renal cell carcinoma                                           
  5212                               Pancreatic cancer                                              
  5213                               Endometrial cancer                                             
  5214                               Glioma                                                         
  5215                               Prostate cancer                                                
  5216                               Thyroid cancer                                                 
  5217                               Basal cell carcinoma                                           
  5218                               Melanoma                                                       
  5219                               Bladder cancer                                                 
  5220                               Chronic myeloid leukemia                                       
  5221                               Acute myeloid leukemia                                         
  5222                               Small cell lung cancer                                         
  5223                               Non-small-cell lung cancer                                     
                                                                                                    
  Immune diseases                    5310                                                           Asthma
  5320                               Autoimmune thyroid disease                                     
  5321                               Inflammatory bowel disease (IBD)                               
  5322                               Systemic lupus erythematosus                                   
  5323                               Rheumatoid arthritis                                           
  5330                               Allograft rejection                                            
  5332                               Graft-versus-host disease                                      
  5340                               Primary immunodeficiency                                       
                                                                                                    
  Neurodegenerative diseases         5010                                                           Alzheimer\'s disease
  5012                               Parkinson\'s disease                                           
  5014                               Amyotrophic lateral sclerosis (ALS)                            
  5016                               Huntington\'s disease                                          
  5020                               Prion diseases                                                 
                                                                                                    
  Substance dependence               5030                                                           Cocaine addiction
  5031                               Amphetamine addiction                                          
  5032                               Morphine addiction                                             
  5033                               Nicotine addiction                                             
  5034                               Alcoholism                                                     
                                                                                                    
  Cardiovascular diseases            5410                                                           Hypertrophic cardiomyopathy (HCM)
  5412                               Arrhythmogenic right ventricular cardiomyopathy (ARVC)         
  5414                               Dilated cardiomyopathy                                         
  5416                               Viral myocarditis                                              
                                                                                                    
  Endocrine and metabolic diseases   4930                                                           Type II diabetes mellitus
  4940                               Type I diabetes mellitus                                       
  4950                               Maturity onset diabetes of the young                           
                                                                                                    
  Infectious diseases: bacterial     5100                                                           Bacterial invasion of epithelial cells
  5110                               *Vibrio cholerae* infection                                    
  5120                               Epithelial cell signaling in *Helicobacter pylori* infection   
  5130                               Pathogenic *Escherichia coli* infection                        
  5131                               Shigellosis                                                    
  5132                               Salmonella infection                                           
  5133                               Pertussis                                                      
  5134                               Legionellosis                                                  
  5150                               *Staphylococcus aureus* infection                              
  5152                               Tuberculosis                                                   
                                                                                                    
  Infectious diseases: viral         5160                                                           Hepatitis C
  5161                               Hepatitis B                                                    
  5162                               Measles                                                        
  5164                               Influenza A                                                    
  5166                               HTLV-I infection                                               
  5168                               Herpes simplex infection                                       
  5169                               Epstein-Barr virus infection                                   
                                                                                                    
  Infectious diseases: parasitic     5140                                                           Leishmaniasis
  5142                               Chagas disease (American trypanosomiasis)                      
  5143                               African trypanosomiasis                                        
  5144                               Malaria                                                        
  5145                               Toxoplasmosis                                                  
  5146                               Amoebiasis                                                     

###### 

Typical disease pathways have high coexpression with ARGs. *r* is the correlation factor; Sa, standard deviation of canonical variables in a (ARGs); Sb, standard deviation of canonical variables in b (disease pathways); Wilks, Wilks\' lambda (likelihood ratio) statistic; and Chisq, Bartlett\'s approximate chi-squared statistic for H(k)0 with Lawley\'s modification.

  Pathway ID   Pathways                                  *r*     Sa       Sb       Wilks          Chisq
  ------------ ----------------------------------------- ------- -------- -------- -------------- ----------
  5166         HTLV-I infection                          0.988   0.0064   0.0119   5.56*E* − 14   129868.5
  5168         Herpes simplex infection                  0.987   0.0064   0.0112   1.22*E* − 11   107961
  5169         Epstein-Barr virus infection              0.987   0.0065   0.0120   4.46*E* − 12   112040.6
  5203         Viral carcinogenesis                      0.987   0.0068   0.0126   1.05*E* − 11   108466.7
  5416         Viral myocarditis                         0.983   0.0073   0.0130   1.24*E* − 07   69145.74
  4940         Type I diabetes mellitus                  0.982   0.0078   0.0145   8.94*E* − 06   50709.06
  5332         Graft-versus-host disease                 0.981   0.0080   0.0141   2.50*E* − 05   46246.41
  5320         Autoimmune thyroid disease                0.981   0.0083   0.0149   2.52*E* − 05   46159.16
  5330         Allograft rejection                       0.980   0.0081   0.0146   6.08*E* − 05   42385.9
  5200         Pathways in cancer                        0.972   0.0091   0.0103   1.39*E* − 14   134581
  5164         Influenza A                               0.964   0.0079   0.0086   7.45*E* − 11   100289.5
  5205         Proteoglycans in cancer                   0.964   0.0116   0.0088   4.19*E* − 12   111889.7
  5152         Tuberculosis                              0.960   0.0083   0.0088   6.84*E* − 11   100606.8
  5202         Transcriptional misregulation in cancer   0.959   0.0107   0.0097   9.35*E* − 11   99265.29
  5016         Huntington\'s disease                     0.958   0.0209   0.0162   1.09*E* − 09   88602.38
  5145         Toxoplasmosis                             0.958   0.0093   0.0089   8.41*E* − 09   80437.34
  5161         Hepatitis B                               0.957   0.0117   0.0101   6.25*E* − 10   91320.55
  5162         Measles                                   0.956   0.0098   0.0105   1.27*E* − 09   88462.56
  5206         MicroRNAs in cancer                       0.956   0.0131   0.0093   4.63*E* − 10   92549.92
  5160         Hepatitis C                               0.952   0.0129   0.0111   3.99*E* − 09   83502.52
  5010         Alzheimer\'s disease                      0.951   0.0192   0.0153   1.18*E* − 09   88451.59

###### 

AIDS-restricted genes have high coexpression with other diseases.

  ID     Pathways                                  ARGs            Pathway genes
  ------ ----------------------------------------- --------------- ---------------
  5166   HTLV-I infection                          HLA-B, HLA-A    3135, 3134
  5168   Herpes simplex infection                  HLA-B, HLA-A    3135, 3134
  5169   Epstein-Barr virus infection              HLA-B, HLA-A    3135, 3134
  5203   Viral carcinogenesis                      HLA-B, HLA-A    3135, 3134
  5416   Viral myocarditis                         HLA-B, HLA-A    3135, 3134
  4940   Type I diabetes mellitus                  HLA-B, HLA-A    3135, 3134
  5332   Graft-versus-host disease                 HLA-B, HLA-A    3135, 3134
  5320   Autoimmune thyroid disease                HLA-B, HLA-A    3135, 3134
  5330   Allograft rejection                       HLA-B, HLA-A    3135, 3134
  5200   Pathways in cancer                        MYH9, ZNRD1     7428, 6772
  5164   Influenza A                               IRF1, ZNRD1     356, 5609
  5205   Proteoglycans in cancer                   MYH9, ZNRD1     5781, 5293
  5152   Tuberculosis                              TLR8, ZNRD1     6772, 3587
  5202   Transcriptional misregulation in cancer   ZNRD1, MYH9     5371, 51513
  5016   Huntington\'s disease                     ZNRD1, TSG101   25981, 55567
  5145   Toxoplasmosis                             MYH9, ZNRD1     2775, 4261
  5161   Hepatitis B                               MYH9, ZNRD1     5111, 356
  5162   Measles                                   NCOR2, ZNRD1    356, 6772
  5206   MicroRNAs in cancer                       MYH9, ZNRD1     7143, 6655
  5160   Hepatitis C                               ZNRD1, GML      6772, 6655
  5010   Alzheimer\'s disease                      NCOR2, ZNRD1    4035, 9377

###### 

Canonical correlation between integrated disease pathway genes and ARGs.

  ID     Pathways                                  Pair ID   Sa     Sb     *r*
  ------ ----------------------------------------- --------- ------ ------ ------
  5211   Renal cell carcinoma                      14        0.26   0.21   0.5
  5213   Endometrial cancer                        12        0.26   0.21   0.51
  5219   Bladder cancer                            11        0.29   0.22   0.5
  5221   Acute myeloid leukemia                    12        0.37   0.21   0.52
  5223   Non-small-cell lung cancer                8         0.23   0.21   0.62
  5310   Asthma                                    4         0.22   0.42   0.66
  5320   Autoimmune thyroid disease                7         0.27   0.4    0.57
  5330   Allograft rejection                       7         0.31   0.26   0.52
  5332   Graft-versus-host disease                 4         0.21   0.23   0.72
  5340   Primary immunodeficiency                  8         0.22   0.24   0.55
  5033   Nicotine addiction                        3         0.35   0.41   0.58
  4940   Type I diabetes mellitus                  6         0.24   0.24   0.64
  5100   Bacterial invasion of epithelial cells    4         0.21   0.49   0.62
  5130   Pathogenic *Escherichia coli* infection   12        0.25   0.21   0.58
  5144   Malaria                                   8         0.24   0.21   0.54

[^1]: Academic Editor: Mohamed Salem
